Abstract 262: HIV-1--Infected Subjects with Low Viremia Have Dysfunctional HDL Compared with Healthy Subjects
Introduction: Dysfunctional HDL may be a novel biomarker of atherosclerotic disease. Using a cell based assay in a small pilot study we have previously demonstrated for the first time that dysfunctional HDL is present in HIV-1-infected persons despite low viremia. However, the cell-based assays of functional properties of HDL are not applicable to large scale clinical studies. It has not been shown in the setting of a case control study whether HIV-1-infected subjects have dysfunctional HDL compared to healthy subjects.
Objectives: To determine whether HIV-1-infected subjects with low viremia (viral load < 50 copies/ml) have dysfunctional HDL compared to healthy subjects using a novel cell free assay
Methods: Using a novel assay based on the effect of HDL on the oxidation of dihydrorhodamine 123 (DHR) (J Lipid Res. 2011 Dec; 52(12):2341-51) we determined oxidative (functional) properties of different HDL samples isolated from plasma from 50 HIV-1 infected patients with low viremia on antiretroviral therapy and from 50 healthy volunteers matched for age and race. The DHR oxidation rate (DOR) in the presence of different samples of HDL was normalized by the DOR value of a control sample (HDL isolated from pooled plasma samples of healthy subjects) and the relative DOR was calculated.
Results: The average relative DOR values from 50 HIV-1-infected patients was 1.46 ±0.29 versus 0.87 ±0.15% in 50 healthy subjects (p<0.0001)(Figure). These results indicate that HIV-1-infected subjects had approximately 60% more dysfunctional HDL compared to healthy subjects.
Conclusions: HIV-1-infected subjects with low viremia have largely dysfunctional HDL compared to healthy subjects. Use of our novel fluorometric method may allow determination of the role of HDL functional phenotype in the development of atherosclerosis in vivo in the setting of clinical studies.
- © 2012 by American Heart Association, Inc.